HOUSTON, TX Sept. 4, 2008. Pharm-Olam International (POI) a multi-national, full service CRO to the pharmaceutical and biotech industries reported today net service revenue growth of 47% for the first half of 2008 vs. the comparative period in 2007. “POI's strong revenues during the first half of 2008 are due to the record sales achieved during 2007 and the earlier part of this year”, said Iain Gordon, VP of Global Business Development. “We are on track for another year of record sales.” Explaining POI's continued success, Gordon said, “We have the largest global spread of any CRO of a comparable size. This local expertise has enabled us to deliver fast patient recruitment and fast regulatory approval that ensures our reputation for timely delivery. A spin off from this has been that we are frequently asked to help in supplemental enrollment for studies managed by either the sponsor or another CRO where recruitment has fallen behind.” POI provided supplemental enrollment for more studies between 2007 and 2008 than in any previous year, recruiting patients in over 25 countries including India, Poland, Serbia, Mexico, USA and Romania. For more information please contact jhovre@pharm-olam.com About Pharm-Olam International |